169 related articles for article (PubMed ID: 17643814)
1. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
2. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
[TBL] [Abstract][Full Text] [Related]
3. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA
Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293
[TBL] [Abstract][Full Text] [Related]
4. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
Gualdrini F; Corvetta D; Cantilena S; Chayka O; Tanno B; Raschellà G; Sala A
Oncotarget; 2010 Aug; 1(4):278-288. PubMed ID: 21304178
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
6. Is MYCN Overexpression Associated With Poor Outcome in
Andrews A; Terry J
Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
[No Abstract] [Full Text] [Related]
7. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM
Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12664-9. PubMed ID: 15314226
[TBL] [Abstract][Full Text] [Related]
8. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
Zhao M; Shu Y; Gu W; Tang H; Mao J
Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
[No Abstract] [Full Text] [Related]
9. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
[TBL] [Abstract][Full Text] [Related]
10. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
11. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
[TBL] [Abstract][Full Text] [Related]
12. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH
Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.
Hartman ML; Talar B; Noman MZ; Gajos-Michniewicz A; Chouaib S; Czyz M
PLoS One; 2014; 9(4):e95157. PubMed ID: 24733089
[TBL] [Abstract][Full Text] [Related]
14. Chelators as Antineuroblastomas Agents.
D'Acunto CW; Gbelcová H; Kaplánek R; Pospíšilová M; Havlík M; Ruml T
Physiol Res; 2023 Oct; 72(S3):S277-S286. PubMed ID: 37888971
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Sun Y; Liu PY; Scarlett CJ; Malyukova A; Liu B; Marshall GM; MacKenzie KL; Biankin AV; Liu T
Oncogene; 2014 Jun; 33(23):2987-94. PubMed ID: 23812427
[TBL] [Abstract][Full Text] [Related]
16. Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.
Stokes ME; Vasciaveo A; Small JC; Zask A; Reznik E; Smith N; Wang Q; Daniels J; Forouhar F; Rajbhandari P; Califano A; Stockwell BR
Cell Chem Biol; 2024 Apr; 31(4):805-819.e9. PubMed ID: 38061356
[TBL] [Abstract][Full Text] [Related]
17. Addiction to B-MYB.
Gustafson WC; Weiss WA
Oncotarget; 2010 Aug; 1(4):235-236. PubMed ID: 21304174
[No Abstract] [Full Text] [Related]
18. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.
Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
PLoS Biol; 2024 Mar; 22(3):e3002240. PubMed ID: 38547242
[TBL] [Abstract][Full Text] [Related]
19. A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.
Dvorkina M; Nieddu V; Chakelam S; Pezzolo A; Cantilena S; Leite AP; Chayka O; Regad T; Pistorio A; Sementa AR; Virasami A; Barton J; Montano X; Lechertier T; Brindle N; Morgenstern D; Lebras M; Burns AJ; Saunders NJ; Hodivala-Dilke K; Bagella L; De The H; Anderson J; Sebire N; Pistoia V; Sala A; Salomoni P
Clin Cancer Res; 2016 Jul; 22(13):3398-409. PubMed ID: 27076624
[TBL] [Abstract][Full Text] [Related]
20. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology.
Kagey MH; He X
Br J Pharmacol; 2017 Dec; 174(24):4637-4650. PubMed ID: 28574171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
